JMP Securities Reiterates Market Outperform on Jasper Therapeutics, Maintains $70 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating for Jasper Therapeutics (NASDAQ:JSPR) and maintained a $70 price target.
September 27, 2024 | 2:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities has reiterated its Market Outperform rating for Jasper Therapeutics, maintaining a $70 price target. This suggests confidence in the company's future performance.
The reiteration of a Market Outperform rating and a high price target by JMP Securities indicates strong confidence in Jasper Therapeutics' potential, likely boosting investor sentiment and positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100